Research programme: Dual-Affinity Re-Targeting anticancer therapeutics - MacroGenics

Drug Profile

Research programme: Dual-Affinity Re-Targeting anticancer therapeutics - MacroGenics

Alternative Names: 5T4 x CD3 DART; DART candidates - MacroGenics/Pfizer; DART Oncology; EphA2xCD3 DART; IL1Ra2xCD3 DART; MGD 013; MGD-15; ROR1xCD3 DART

Latest Information Update: 12 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MacroGenics
  • Class Bispecific antibodies; Proteins
  • Mechanism of Action CD223 antigen inhibitors; CD3 antigen modulators; Interleukin 13 receptor modulators; PDCD 1 protein inhibitors; Receptor tyrosine kinase-like orphan receptor modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 03 May 2017 MacroGenics files an IND application for Cancer
  • 01 Apr 2017 Pharmacokinetics data from preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 03 Aug 2016 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top